Search alternatives:
point decrease » point increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
5 w » 5 wt (Expand Search)
Showing 41 - 60 results of 66,812 for search '(( 5 ((mean decrease) OR (a decrease)) ) OR ((( 5 w decrease ) OR ( e point decrease ))))', query time: 1.17s Refine Results
  1. 41
    Low oscillatory shar stress <i>Arf6</i> heterozygosity decreases Arf6 expression.

    Low oscillatory shar stress <i>Arf6</i> heterozygosity decreases Arf6 expression. by Venkateswara R. Gogulamudi (15447428)

    Published 2023
    Save to List
    Saved in:
  2. 42
    Nsp8 decreases antiviral immune and inflammatory responses and promotes SARS-CoV-2 infection.

    Nsp8 decreases antiviral immune and inflammatory responses and promotes SARS-CoV-2 infection. by Xiaolin Zhang (246784)

    Published 2023
    Save to List
    Saved in:
  3. 43
    Comparison of wind roses between ERA5 reanalysis and in-situ measured data. a: W03 station, b: W08 station, c: W13 station and d: W19 station.

    Comparison of wind roses between ERA5 reanalysis and in-situ measured data. a: W03 station, b: W08 station, c: W13 station and d: W19 station. by Weidong Ji (129916)

    Published 2025
    Save to List
    Saved in:
  4. 44
    Activating cAMP synthesis decreases liberation of propionyl-CoA from cholesterol.

    Activating cAMP synthesis decreases liberation of propionyl-CoA from cholesterol. by Kaley M. Wilburn (12060476)

    Published 2022
    Save to List
    Saved in:
  5. 45
    Total viable immune cells and macrophages decrease acutely while neutrophils and macrophage increase at day 30 in parotid glands after 5Gy IR.

    Total viable immune cells and macrophages decrease acutely while neutrophils and macrophage increase at day 30 in parotid glands after 5Gy IR. by Jordan A. Gunning (18143970)

    Published 2024
    Save to List
    Saved in:
  6. 46
    Downregulation of DOM decreases the abundance of PER and TIM.

    Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

    Published 2019
    “…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”
    Save to List
    Saved in:
  7. 47
    Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W19 station).

    Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W1... by Weidong Ji (129916)

    Published 2025
    Save to List
    Saved in:
  8. 48
    TREM1 inhibition decreases HIV mediated inflammatory cytokine production.

    TREM1 inhibition decreases HIV mediated inflammatory cytokine production. by Jinhee Hyun (6900683)

    Published 2019
    Save to List
    Saved in:
  9. 49
    S5 Fig -

    S5 Fig - by Jordan K. Abbott (8934239)

    Published 2022
    Save to List
    Saved in:
  10. 50
    Equilibrium points and their corresponding eigenvalues of Eq (5).

    Equilibrium points and their corresponding eigenvalues of Eq (5). by Xinghua Fan (7344632)

    Published 2019
    Save to List
    Saved in:
  11. 51
    The spectral sensitivity of European seabass fed a 5% taurine diet.

    The spectral sensitivity of European seabass fed a 5% taurine diet. by Richard W. Brill (2337940)

    Published 2019
    Save to List
    Saved in:
  12. 52
    MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG.

    MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

    Published 2024
    Save to List
    Saved in:
  13. 53
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 54
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 55
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 56
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 57
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 58
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 59
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 60
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: